Exercise or conversion
Kathryn Guarini
Director
Common Stock
- Value context
- $287.75K
- Reported price
- $719.37 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
REGENERON PHARMACEUTICALS, INC.
Last 30 daysNo qualifying insider buying. No qualifying insider sales.
Showing the first 6 of 12 trades on this page.
Director
Common Stock
Director
Non-Qualified Stock Option (right to buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP General Counsel and Secret
Common Stock
EVP General Counsel and Secret
Common Stock
EVP General Counsel and Secret
Non-Qualified Stock Option (right to buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
EVP Finance CFO
Common Stock
EVP Finance CFO
Common Stock
EVP Finance CFO
Non-Qualified Stock Option (right to buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Director
Common Stock
Director
Non-Qualified Stock Option (right to buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Director
Common Stock
Director
Non-Qualified Stock Option (right to buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common StockOption exercise or conversion10b5-1 | 400$719.37 / share | $287.75K | Sep 2Filed Sep 3 · 1d later | SEC filing |
| Director | Non-Qualified Stock Option (right to buy)Option exercise or conversion10b5-1 | Derivative units400$719.37 exercise / conversion price | Not a separate purchase | Sep 2Filed Sep 3 · 1d later | SEC filing |
| EVP General Counsel and Secret | Common StockOption exercise or conversion | 12,282$381.92 / share | $4.69M | Aug 19Filed Aug 21 · 2d later | SEC filing |
| EVP General Counsel and Secret | Common StockExercise-price or tax withholding | 9,019$830.15 / share | $7.49M | Aug 19Filed Aug 21 · 2d later | SEC filing |
| EVP General Counsel and Secret | Non-Qualified Stock Option (right to buy)Option exercise or conversion | Derivative units12,282$381.92 exercise / conversion price | Not a separate purchase | Aug 19Filed Aug 21 · 2d later | SEC filing |
| EVP Finance CFO | Common StockOption exercise or conversion | 6,283$381.92 / share | $2.4M | Aug 18Filed Aug 20 · 2d later | SEC filing |
| EVP Finance CFO | Common StockExercise-price or tax withholding | 4,599$813.47 / share | $3.74M | Aug 18Filed Aug 20 · 2d later | SEC filing |
| EVP Finance CFO | Non-Qualified Stock Option (right to buy)Option exercise or conversion | Derivative units6,283$381.92 exercise / conversion price | Not a separate purchase | Aug 18Filed Aug 20 · 2d later | SEC filing |
| Director | Common StockOption exercise or conversion10b5-1 | 400$719.37 / share | $287.75K | Aug 10Filed Aug 12 · 2d later | SEC filing |
| Director | Non-Qualified Stock Option (right to buy)Option exercise or conversion10b5-1 | Derivative units400$719.37 exercise / conversion price | Not a separate purchase | Aug 10Filed Aug 12 · 2d later | SEC filing |
| Director | Common StockOption exercise or conversion10b5-1 | 800$376.69 / share | $301.35K | Aug 10Filed Aug 12 · 2d later | SEC filing |
| Director | Non-Qualified Stock Option (right to buy)Option exercise or conversion10b5-1 | Derivative units800$376.69 exercise / conversion price | Not a separate purchase | Aug 10Filed Aug 12 · 2d later | SEC filing |
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
Regeneron Pharmaceuticals, Inc. - Common Stock · Stock
The filing reports a purchase for the member.
Regeneron Pharmaceuticals, Inc. - Common Stock (REGN) · Stock
The filing reports a sale for the member.
Gilbert CisnerosReporting House memberRegeneron Pharmaceuticals, Inc. - Common Stock (REGN) · Stock
The filing reports a purchase for the member.
Julia LetlowReporting House memberRegeneron Pharmaceuticals, Inc. - Common Stock (REGN) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House member